| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 24, 2024 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
8-K - IRIDEX CORP (0001006045) (Filer)
10-Q - IRIDEX CORP (0001006045) (Filer)
8-K - IRIDEX CORP (0001006045) (Filer)
SC 13D - IRIDEX CORP (0001006045) (Subject)
SC 13D - IRIDEX CORP (0001006045) (Subject)
SC 13G/A - IRIDEX CORP (0001006045) (Subject)
MOUNTAIN VIEW, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today confirms that Local Coverage Determination (LCD) L37531, relating to Micro-Invasive Glaucoma Surgery (MIGS), was adopted as scheduled and will be effective for services performed on or after November 17, 2024. The Company has previously reported that it believes the reimbursement limitations created by the new LCD has potential to significantly increase physician interest in and use of Iridex's advanced laser-based treatmen
MOUNTAIN VIEW, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended September 28, 2024. Third Quarter 2024 Financial and Recent Highlights Expects to achieve EBITDA breakeven in the fourth quarter of 2024 as a result of actions to reduce costs and improve profitabilityGenerated total revenue of $11.6 million, representing a decline of 8% sequentially from the second quarter of 2024 and a decline of 10% over Q3'23Cyclo G6® product fami
MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter 2024 and provide a business update after the close of trading on Tuesday, November 12, 2024. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing 1-888-596-4144 for domestic callers or +1-646-968-2525 for interna
Roth Capital reiterated coverage of Iridex with a rating of Buy and set a new price target of $11.00 from $9.00 previously
Roth Capital reiterated coverage of IRIDEX with a rating of Buy and set a new price target of $9.00 from $6.00 previously
Roth Capital reiterated coverage of Iridex with a rating of Buy and set a new price target of $9.00 from $6.00 previously
4 - IRIDEX CORP (0001006045) (Issuer)
4 - IRIDEX CORP (0001006045) (Issuer)
4 - IRIDEX CORP (0001006045) (Issuer)
Stifel analyst Thomas Stephan maintains Iridex (NASDAQ:IRIX) with a Hold and maintains $2 price target.
MOUNTAIN VIEW, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended September 28, 2024. Third Quarter 2024 Financial and Recent Highlights Expects to achieve EBITDA breakeven in the fourth quarter of 2024 as a result of actions to reduce costs and improve profitabilityGenerated total revenue of $11.6 million, representing a decline of 8% sequentially from the second quarter of 2024 and a decline of 10% over Q3'23Cyclo G6® product fami
MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter 2024 and provide a business update after the close of trading on Tuesday, November 12, 2024. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing 1-888-596-4144 for domestic callers or +1-646-968-2525 for interna
MOUNTAIN VIEW, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended June 29, 2024, and provided a business update. Second Quarter 2024 Financial and Recent Highlights Generated total revenue of $12.6 million, representing sequential growth of 7% from the first quarter of 2024Cyclo G6® product family revenue was $3.3 million, representing sequential growth of 13% from the first quarter of 2024 Sold 15,100 Cyclo G6 probes, compared to
MOUNTAIN VIEW, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the appointment of Patrick Mercer as the Company's Chief Executive Officer and President effective October 1, 2024. Previously Mr. Mercer served as the Company's Chief Operating Officer and President. David Bruce, the Company's prior Chief Executive Officer, is transitioning from the Company. Coincident to Mr. Mercer's appointment, Scott Shuda was appointed Executive Chairman of the Company's board of directors. M
MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation, headquartered in Mountain View, California, and Imperial College Healthcare NHS Trust in London, today announced the first patient enrollment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulse® Transscleral Laser Therapy (TLT) using Iridex' Cyclo G6® Laser and the MicroPulse P3® Delivery Device. This partnership establishes a large-scale enrollment platform to advance clinical research. David I. Bruce, President and CEO of Iridex, shared: "The first patient enrollment in this partnership with Imperial College Healthcare NHS Trust is the first step toward mu
MOUNTAIN VIEW, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the appointment of Beverly Huss to its board of directors, effective, March 17, 2022. In connection with Ms. Huss' appointment to the board, the size of the board was increased from five to six members as of the Effective Date. "I am very pleased to welcome Beverly to our board of directors," said Scott Shuda, chairman of the board of Iridex. "Beverly's extensive management and board experience in the medical device industry and proven track record with non-invasive a